TG Therapeutics Inc. (TGTX)

7.77
0.31 4.16
NASDAQ : Health Technology
Prev Close 7.46
Open 7.46
Day Low/High 7.45 / 7.87
52 Wk Low/High 3.32 / 14.65
Volume 1.17M
Avg Volume 1.81M
Exchange NASDAQ
Shares Outstanding 90.83M
Market Cap 659.46M
EPS -2.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Commit To Buy TG Therapeutics At $10, Earn 29.1% Annualized Using Options

Investors eyeing a purchase of TG Therapeutics Inc shares, but cautious about paying the going market price of $11.43/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $10 strike, which has a bid at the time of this writing of $1.15.

TG Therapeutics, Inc. To Present At The 27th Annual Oppenheimer Healthcare Conference

Presentation Scheduled for Tuesday, March 21, 2017 at 3:20pm ET

TG Therapeutics, Inc. To Present At The 29th Annual ROTH Conference

Presentation Scheduled for Tuesday, March 14, 2017 at 3:00pm PT

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

Biotech Stock Mailbag: Puma's Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2016 Financial Results And Business Update

Investor Conference Call to be held Friday, March 10, 2017 at 8:30am ET

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.

How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More

How to Trade Monday's Most Active Stocks - Snap, GM, TG Therapeutics and More

These stocks are showing short-term gain catalysts and longer-term growth potential. Here's how to trade them.

Notable Monday Option Activity: TGTX, OMED, KMB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in TG Therapeutics Inc , where a total volume of 3,146 contracts has been traded thus far today, a contract volume which is representative of approximately 314,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 78.1% of TGTX's average daily trading volume over the past month, of 403,030 shares.

DEADLINE ALERT: Brower Piven Reminds Investors Of The March 7, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Publication of Clinical Data From The Phase 1/2 Trial Of TG-1101 (ublituximab) Monotherapy In The British Journal Of Haematology

Single agent TG-1101 treatment resulted in 45% ORR in NHL and CLL patients previously exposed to rituximab, with a 31% ORR observed in rituximab-refractory patients

TGTX SHAREHOLDER REMINDER: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc.

TG Therapeutics, Inc. To Present At The 2017 BIO CEO & Investor Conference

Presentation Scheduled for Monday, February 13, 2017 at 9:00am ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed A Class Action Lawsuit Against TG Therapeutics, Inc. And Announces A Lead Plaintiff Deadline Of March 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc.

TGTX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving TG Therapeutics, Inc. And A Lead Plaintiff Deadline Of March 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased TG Therapeutics, Inc.

TG Therapeutics Enters Oversold Territory (TGTX)

TG Therapeutics Enters Oversold Territory (TGTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D- (Sell)